Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer

被引:170
作者
Flanagan, FL
Dehdashti, F
Ogunbiyi, OA
Kodner, IJ
Siegel, BA
机构
[1] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Div Nucl Med, St Louis, MO USA
[2] Washington Univ, Sch Med, Dept Surg, Div Colon & Rectal Surg, St Louis, MO USA
关键词
D O I
10.1097/00000658-199803000-00001
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To assess the potential role of positron emission tomography (PET) with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) in patients with unexplained rising carcinoembryonic antigen (CEA) levels after the treatment of colorectal cancer, Background A rising CEA level after the resection of colorectal cancer is an early indicator of tumor recurrence. However, conventional imaging techniques have limited sensitivity for detecting recur rent disease in such patients, Especially after surgical intervention, FDG-PET is rapidly gaining an important role in establishing the extent of disease in the oncology patient, Methods Twenty-two patients with abnormal CEA levels and normal results of conventional methods of tumor detection were studied with FDG-PET, The PET results were compared with pathologic findings (n = 9) and long-term radiologic and clinical follow-up (n = 13). Results FDG-PET was abnormal in 17 of 22 patients. Tissue sampling was available in 7 of these 17 patients; all of these had recurrent disease. Definitive curative surgical intervention was performed in four patients, Subsequent dedicated imaging findings and clinical course confirmed the presence of extensive disease in 8 of the remaining 10 patients; the PET results in the other 2 patients were considered falsely positive. FDG-PET was negative in 5 of 22 patients. No disease was found by tissue sampling (n = 2) and clinical follow-up (n = 3), Overall, the positive-predictive value for PET was 89%, (15 of 17) and the negative-predictive value was 100% (5 of 5). Conclusions When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have a rising CEA level after colorectal surgery.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 36 条
  • [1] CLINICAL-APPLICATIONS OF INDIUM-111-LABELED MONOCLONAL-ANTIBODY IMAGING IN COLORECTAL-CANCER PATIENTS
    ABDELNABI, H
    DOERR, RJ
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1993, 23 (02) : 99 - 113
  • [2] CLINICAL-VALUE OF WHOLE-BODY POSITRON EMISSION TOMOGRAPHY WITH [F-18] FLUORODEOXYGLUCOSE IN RECURRENT COLORECTAL-CANCER
    BEETS, G
    PENNINCKX, F
    SCHIEPERS, C
    FILEZ, L
    MORTELMANS, L
    KERREMANS, R
    AERTS, R
    DEROO, M
    [J]. BRITISH JOURNAL OF SURGERY, 1994, 81 (11) : 1666 - 1670
  • [3] IN-111 ONCOSCINT CR/OV AND F-18 FDG IN COLORECTAL AND OVARIAN-CARCINOMA RECURRENCES - EARLY OBSERVATIONS
    BOHDIEWICZ, PJ
    SCOTT, GC
    JUNI, JE
    FINKBENNETT, D
    WILNER, F
    NAGLE, C
    DWORKIN, HJ
    [J]. CLINICAL NUCLEAR MEDICINE, 1995, 20 (03) : 230 - 236
  • [4] Cohen AM, 1993, Cancer: principles and practice o f oncology, P929
  • [5] PET and [F-18]-FDG in oncology: A clinical update
    Conti, PS
    Lilien, DL
    Hawley, K
    Keppler, J
    Grafton, ST
    Bading, JR
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) : 717 - 735
  • [6] GOLDENBERG DM, 1992, J NUCL MED, V33, P803
  • [7] HABERKORN U, 1991, J NUCL MED, V32, P1485
  • [8] HASEMAN MK, 1992, J NUCL MED, V33, P1750
  • [9] Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques
    Hida, JI
    Yasutomi, M
    Shindoh, K
    Kitaoka, M
    Fujimoto, K
    Ieda, S
    Machidera, N
    Kubo, R
    Morikawa, E
    Inufusa, H
    Watatani, M
    Okuno, K
    [J]. DISEASES OF THE COLON & RECTUM, 1996, 39 (01) : 74 - 79
  • [10] RECURRENT RECTAL-CANCER AND SCAR DIFFERENTIATION WITH PET AND MR IMAGING
    ITO, K
    KATO, T
    TADOKORO, M
    ISHIGUCHI, T
    OSHIMA, M
    ISHIGAKI, T
    SAKUMA, S
    [J]. RADIOLOGY, 1992, 182 (02) : 549 - 552